» Articles » PMID: 16424164

Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function

Overview
Journal J Immunol
Date 2006 Jan 21
PMID 16424164
Citations 254
Authors
Affiliations
Soon will be listed here.
Abstract

Many tumor cells shed specialized membrane vesicles known as exosomes. In this study, we show that pretreatment of mice with exosomes produced by TS/A or 4T.1 murine mammary tumor cells resulted in accelerated growth of implanted tumor cells in both syngeneic BALB/c mice and nude mice. As implanted TS/A tumor cells grew more rapidly in mice that had been depleted of NK cells, we analyzed the effects of the tumor-derived exosomes on NK cells. The tumor-derived exosomes inhibit NK cell cytotoxic activity ex vivo and in vitro as demonstrated by chromium release assays. The treatment of mice with TS/A tumor exosomes also led to a reduction in the percentages of NK cells, as determined by FACS analysis, in the lungs and spleens. Key features of NK cell activity were inhibited, including release of perforin but not granzyme B, as well as the expression of cyclin D3 and activation of the Jak3-mediated pathways. Human tumor cell lines also were found to produce exosomes that were capable of inhibiting IL-2-stimulated NK cell proliferation. Exosomes produced by dendritic cells or B cells did not. The presentation of tumor Ags by exosomes is under consideration as a cancer vaccine strategy; however, we found that pretreatment of mice with tumor exosomes blunted the protective effect of syngeneic dendritic cells pulsed ex vivo with tumor exosomes. We propose that tumor exosomes contribute to the growth of tumors by blocking IL-2-mediated activation of NK cells and their cytotoxic response to tumor cells.

Citing Articles

Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.

Mohseni A, Salehi F, Rostami S, Hadiloo K, Hashemi M, Baridjavadi Z Stem Cell Res Ther. 2025; 16(1):6.

PMID: 39773361 PMC: 11708188. DOI: 10.1186/s13287-024-04125-0.


The theragnostic advances of exosomes in managing leukaemia.

Ghosh S, Dey A, Chakrabarti A, Bhuniya T, Indu N, Hait A J Cell Mol Med. 2024; 28(23):e70052.

PMID: 39659020 PMC: 11632122. DOI: 10.1111/jcmm.70052.


Exploring exosomes: novel diagnostic and therapeutic frontiers in thyroid cancer.

Zhang S, Yang Y, Wang D, Yang X, Cai Y, Shui C Front Pharmacol. 2024; 15:1431581.

PMID: 39584141 PMC: 11581896. DOI: 10.3389/fphar.2024.1431581.


Insights in AAV-mediated antigen-specific immunity and a strategy for AAV vaccine dose reduction through AAV-extracellular vesicle association.

Molina E, Tejero M, Duzenli O, Kuoch H, Caine C, Krotova K Mol Ther Methods Clin Dev. 2024; 32(4):101358.

PMID: 39559560 PMC: 11570487. DOI: 10.1016/j.omtm.2024.101358.


Therapeutic potential of exosomes derived from mesenchymal stem cells for treatment of systemic lupus erythematosus.

Samavati S, Yarani R, Kiani S, Hoseinkhani Z, Mehrabi M, Levitte S J Inflamm (Lond). 2024; 21(1):20.

PMID: 38867277 PMC: 11170788. DOI: 10.1186/s12950-024-00381-2.